Foundation Medicine (FMI) Tops Q1 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Foundation Medicine (FMI) Tops Q1 EPS by 22c
May 3, 2016 4:04 PM EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Foundation
Medicine, Inc. (NASDAQ: FMI) today reported financial and operating
results for its first quarter ended March 31, 2016. Highlights for the
quarter included:
Achieved first quarter revenue of $30.4 million, 57% year-over-year
growth;
Reported 8,985 clinical tests in the first quarter, 14% year-over-year
growth;
Grew the FoundationCORE molecular information
knowledgebase, now approaching 80,000 patient cases;...
More
May 3, 2016 4:02 PM EDT
-- Blood-based Genomic Profiling Assay Provides New Option for Cancer
Patients Who Are Not Candidates for Tissue Biopsy --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the launch of
FoundationACT (Assay for Circulating Tumor DNA), an analytically
validated and accurate blood-based circulating tumor DNA (ctDNA) assay
that provides patients and oncologists with a new option for
comprehensive genomic profiling when a tissue biopsy is not feasible or
when tissue is not available. By analyzing circulating tumor DNA
isolated from a patients blood, FoundationACT can identify clinically... More
